Glycostem’s pipeline has the potential to redefine standards of care across various type of cancer where there is an urgent medical need.
Therapy |
Indication |
Development |
Pre-clinical |
Phase I |
Phase II |
Phase III |
Market Introduction |
Partner |
|---|---|---|---|---|---|---|---|---|
Blood Cancer - Acute Myeloid Leukemia |
color |
color |
color |
Q2 2020 |
2nd half 2023 |
US: Glycostem; EU: Glycostem; JP: undisclosed; KR: undisclosed |
||
Blood Cancer - Multiple Myeloma |
color |
color |
color |
Q1 2021 |
2nd half 2023 |
US: Glycostem; EU: Glycostem; JP: undisclosed; KR: undisclosed |
||
Solid Tumors - Investigational pre-conditioning (Investigator Initiated Trial) |
color |
TBA |
||||||
Solid Tumors - Adjuvant post-surgery with alternative pre-conditioning |
color |
TBA |
Therapy |
Indication |
Development |
Pre-clinical |
Phase I |
Phase II |
Phase III |
Market introduction |
Partner |
|---|---|---|---|---|---|---|---|---|
TCR-NK |
Early stage, tbd |
color |
color |
TBA |
Zelluna |